$INTI
Inhibitor Therapeutics, Inc.

2018 Q4 Form 10-Q Financial Statement

#000119312518326293 Filed on November 14, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $674.2K $400.1K $250.0K
YoY Change 82.23% 60.03% -75.25%
% of Gross Profit
Research & Development $655.3K $775.4K $433.5K
YoY Change 23.64% 78.86% -39.81%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.330M $1.176M $681.2K
YoY Change 46.1% 72.58% -60.72%
Operating Profit -$1.176M -$681.2K
YoY Change 72.58% -60.72%
Interest Expense $3.320K $4.000K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.326M -$1.172M -$680.0K
YoY Change 47.35% 72.28% -60.69%
Income Tax
% Of Pretax Income
Net Earnings -$1.326M -$1.172M -$679.1K
YoY Change 47.35% 72.52% -60.63%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$3.585K -$3.167K $0.00
COMMON SHARES
Basic Shares Outstanding 370.0M shares 370.0M shares 369.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.109M $1.441M $890.0K
YoY Change 226.09% 61.89% -74.93%
Cash & Equivalents $1.109M $1.441M $887.4K
Short-Term Investments
Other Short-Term Assets $41.30K $51.44K $300.0K
YoY Change -86.68% -82.85% 409.3%
Inventory
Prepaid Expenses $41.30K $51.44K $51.95K
Receivables
Other Receivables
Total Short-Term Assets $1.150M $1.742M $1.189M
YoY Change 75.37% 46.49% -67.08%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $82.99K $90.32K $119.6K
YoY Change -26.09% -24.49% -52.16%
Total Long-Term Assets $82.99K $90.32K $119.6K
YoY Change -26.09% -24.49% -52.16%
TOTAL ASSETS
Total Short-Term Assets $1.150M $1.742M $1.189M
Total Long-Term Assets $82.99K $90.32K $119.6K
Total Assets $1.233M $1.833M $1.309M
YoY Change 60.54% 40.01% -66.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $384.8K $328.0K $218.7K
YoY Change -28.06% 50.0% -50.47%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $700.7K $549.1K $252.2K
YoY Change 16.49% 117.71% -46.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $500.0K $0.00
YoY Change
Total Long-Term Liabilities $500.0K $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $700.7K $549.1K $252.2K
Total Long-Term Liabilities $500.0K $0.00 $0.00
Total Liabilities $1.201M $549.1K $252.2K
YoY Change 99.61% 117.71% -46.29%
SHAREHOLDERS EQUITY
Retained Earnings -$52.98M -$51.60M -$47.37M
YoY Change 9.75% 8.94% 17.19%
Common Stock $49.05M $48.93M $48.43M
YoY Change 1.26% 1.03% 10.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $32.35K -$2.677M $1.057M
YoY Change
Total Liabilities & Shareholders Equity $1.233M $1.833M $1.309M
YoY Change 60.54% 40.01% -66.11%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$1.326M -$1.172M -$679.1K
YoY Change 47.35% 72.52% -60.63%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$832.1K -$956.2K -$760.0K
YoY Change 54.1% 25.81% -28.3%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 500.0K 1.603M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -832.1K -956.2K -760.0K
Cash From Investing Activities
Cash From Financing Activities 500.0K 1.603M 0.000
Net Change In Cash -332.1K 646.7K -760.0K
YoY Change -38.5% -185.09% -28.3%
FREE CASH FLOW
Cash From Operating Activities -$832.1K -$956.2K -$760.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
369959064 shares
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
887361
CY2018Q3 us-gaap Assets Current
AssetsCurrent
1742267
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
48889682
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
328001
CY2018Q3 us-gaap Assets
Assets
1832582
CY2018Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1440826
CY2018Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1200000
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
369959064 shares
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
369959064 shares
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
36996
CY2018Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
250000
CY2018Q3 us-gaap Dividends Payable Current
DividendsPayableCurrent
49534
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
549080
CY2018Q3 us-gaap Liabilities
Liabilities
549080
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1832582
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
90315
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
51441
CY2018Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
171545
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623 shares
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-51604042
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
-2677364
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6885422
CY2017Q4 us-gaap Assets Current
AssetsCurrent
655768
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
48403523
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
534956
CY2017Q4 us-gaap Assets
Assets
768052
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
344113
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
369599266 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
369599266 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
36960
CY2017Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
250000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
601489
CY2017Q4 us-gaap Liabilities
Liabilities
601489
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
768052
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
112284
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
61655
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
66533
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48273920
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
166563
CY2018Q3 us-gaap Common Stock Dividends Shares
CommonStockDividendsShares
184798 shares
CY2018Q3 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
60000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5998061
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2521029
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-31112
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
16726
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-55931
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3628227
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2369834
us-gaap Net Income Loss
NetIncomeLoss
-4196948
us-gaap Operating Expenses
OperatingExpenses
4213674
us-gaap Operating Income Loss
OperatingIncomeLoss
-4213674
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
49500
us-gaap Profit Loss
ProfitLoss
-4196948
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1692645
us-gaap Share Based Compensation
ShareBasedCompensation
1851933
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
365618815 shares
hppi Net Settlement In Connection With Issuance Of Shares Associated With Restricted Stock Units
NetSettlementInConnectionWithIssuanceOfSharesAssociatedWithRestrictedStockUnits
3677727
hppi Fair Value Of Shares Withheld With Net Settlement Transaction
FairValueOfSharesWithheldWithNetSettlementTransaction
3677727
hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-4196948
dei Amendment Flag
AmendmentFlag
false
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
417647
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1096713
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Type
DocumentType
10-Q
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
106082
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
dei Entity Central Index Key
EntityCentralIndexKey
0001042418
us-gaap Dividends Preferred Stock
DividendsPreferredStock
106082
dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
dei Entity Small Business
EntitySmallBusiness
true
dei Document Period End Date
DocumentPeriodEndDate
2018-09-30
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1256453
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-32183
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
10707
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-101943
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3972866
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2876153
us-gaap Net Income Loss
NetIncomeLoss
-3224040
us-gaap Operating Expenses
OperatingExpenses
3234747
us-gaap Operating Income Loss
OperatingIncomeLoss
-3234747
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
12000
us-gaap Profit Loss
ProfitLoss
-3224040
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1978294
us-gaap Share Based Compensation
ShareBasedCompensation
417647
us-gaap Stock Issued1
StockIssued1
56548
dei Trading Symbol
TradingSymbol
HPPI
us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
56548
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <i>Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
369757743 shares
hppi Proceeds From The Sale Of Preferred Stock And Common Stock Warrants Related Party Net
ProceedsFromTheSaleOfPreferredStockAndCommonStockWarrantsRelatedPartyNet
3960866
hppi Stock Issued During Period Value New Issues To Related Party
StockIssuedDuringPeriodValueNewIssuesToRelatedParty
0
hppi Issuance Of Common Stock Upon Exercise Of Warrants
IssuanceOfCommonStockUponExerciseOfWarrants
12000
hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-3330122
hppi Accrued But Unpaid Dividends
AccruedButUnpaidDividends
49534
hppi Stock Issued During Period Shares New Issues To Related Party
StockIssuedDuringPeriodSharesNewIssuesToRelatedParty
0 shares
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
247621
CY2017Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2086
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-679080
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
681166
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-681166
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
433545
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
369599266 shares
CY2017Q3 hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-679080
CY2018Q3 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
49534
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
400076
CY2018Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3995
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-1171530
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
1175525
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1175525
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
775449
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
369930943 shares
CY2018Q3 hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-1221064

Files In Submission

Name View Source Status
0001193125-18-326293-index-headers.html Edgar Link pending
0001193125-18-326293-index.html Edgar Link pending
0001193125-18-326293.txt Edgar Link pending
0001193125-18-326293-xbrl.zip Edgar Link pending
d613945d10q.htm Edgar Link pending
d613945dex311.htm Edgar Link pending
d613945dex312.htm Edgar Link pending
d613945dex321.htm Edgar Link pending
d613945dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hppi-20180930.xml Edgar Link completed
hppi-20180930.xsd Edgar Link pending
hppi-20180930_cal.xml Edgar Link unprocessable
hppi-20180930_def.xml Edgar Link unprocessable
hppi-20180930_lab.xml Edgar Link unprocessable
hppi-20180930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending